Welcome to our dedicated page for Organovo Holdings news (Ticker: ONVO), a resource for investors and traders seeking the latest updates and insights on Organovo Holdings stock.
Organovo Holdings Inc. (NYSE MKT: ONVO) is a pioneering biotechnology company that designs and creates functional, three-dimensional (3D) human tissues for medical research and therapeutic applications. The company collaborates with pharmaceutical and academic partners to develop human biological disease models in 3D, which can potentially accelerate the drug discovery process, enabling treatments to be developed faster and at lower costs.
Organovo's lead molecule, FXR314, is currently under development for the treatment of inflammatory bowel disease (IBD), including ulcerative colitis (UC). This initiative is based on demonstrated clinical promise in 3D human tissues and robust preclinical data. FXR314 also shows potential applications in metabolic liver diseases and oncology.
The company’s proprietary technology enables the construction of 3D human tissues that mimic critical aspects of native human tissue composition, architecture, function, and disease. These advancements have been prominently featured in numerous scientific publications and media outlets such as The Wall Street Journal, Time Magazine, and The Economist.
Financially, Organovo is gearing up for a public offering expected to close around May 13, 2024, with gross proceeds anticipated to be approximately $5.25 million, excluding potential proceeds from the exercise of common warrants. JonesTrading Institutional Services LLC is acting as the exclusive placement agent for this offering. The company’s financial health and strategic investments position it well for future growth and innovations.
Organovo continues to push the boundaries of medical research and practice, leveraging its groundbreaking technology to improve healthcare outcomes. With ongoing projects and collaborations, the company remains at the forefront of biotechnology, aiming to revolutionize treatments and therapies across various medical fields.
Organovo Holdings, Inc. (NASDAQ: ONVO) has announced its clinical program for FXR314, an FXR agonist that has completed initial trials with positive safety and tolerability results. The drug is approved for a Phase 2 trial targeting ulcerative colitis. The company emphasizes that FXR314 could be a superior option compared to existing FXR-directed therapies, aiming to minimize dose-limiting toxicity. Additionally, the company updated its timeline, moving the start of Phase 1 trials to 2025, with further guidance on Phase 2 forthcoming. Organovo specializes in developing therapies utilizing advanced 3D human tissue models.
Organovo Holdings (ONVO) has achieved a significant milestone in developing a three-dimensional model for inflammatory bowel disease (IBD), particularly Crohn's disease. The model has been validated for target identification and therapeutic opportunities, demonstrating the ability to reproduce disease characteristics and reduce symptoms through targeted treatments. Organovo aims to advance at least one target to medicinal chemistry by the end of 2022, seeking to create a proprietary drug for Crohn's disease, a condition affecting over 1 million individuals in North America.
Organovo Holdings, focusing on innovative 3D tissue models for drug development, announced Executive Chairman Keith Murphy's participation in the H.C. Wainwright 24th Annual Global Investment Conference from September 12-14, 2022. The company aims to advance drug development for Crohn’s Disease, having recently established its first 3D tissue model. A corporate presentation will be webcast on September 12, 2022, at 7:00 AM ET. Investors can access the archived presentation on Organovo's website for 90 days.
Organovo Holdings (ONVO) announces the postponement of its 2022 Annual Meeting from September 7 to October 12, 2022, at 9:00 AM PT. This decision was made after the company received less than 35% of proxies by the previous record date, July 15, 2022. The new record date is set for September 7, 2022. The meeting will be conducted virtually to enhance stockholder participation. An amended proxy statement will be filed promptly with the SEC, providing updated information regarding the meeting.
Organovo Holdings, Inc. (Nasdaq: ONVO) has successfully advanced its first inflammatory bowel disease (IBD) model for Crohn’s disease, marking a significant step in drug discovery. The model demonstrates key aspects of patient biology and is positioned to identify therapeutics. The company aims to complete target validation by March 2023, with a goal to file for an investigational new drug (IND) application by 2025. Organovo is positioning itself to leverage its 3D tissue technologies for innovative drug development, focusing on several pipeline programs for IBD.
Organovo Holdings (Nasdaq: ONVO) has announced a licensing agreement with BICO, allowing the latter to utilize Organovo's foundational patent portfolio in 3D bioprinting. This collaboration marks a significant step, as it resolves previous legal disputes over potential patent infringements. Under this agreement, all civil actions regarding these patents are dismissed. The partnership aims to enhance the capabilities of BICO's product lines, facilitating further advancements in 3D bioprinting technology.
FAQ
What is the current stock price of Organovo Holdings (ONVO)?
What is the market cap of Organovo Holdings (ONVO)?
What does Organovo Holdings Inc. specialize in?
What is the significance of FXR314?
Who are Organovo's partners?
How does Organovo's technology benefit drug discovery?
What are the financial highlights of Organovo?
Which diseases is FXR314 targeting?
Where has Organovo's technology been featured?
What are the potential benefits of Organovo's 3D tissues?
What is Organovo's latest financial move?
Who is the placement agent for Organovo's public offering?
